John Libbey Eurotext




Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study
European Journal of Dermatology. Volume 20, Number 4, 465-71, July-August 2010, Therapy
Free Article
Author(s) : Colin Fleming, Cecilia Ganslandt, Lyn Guenther, Anders Johannesson, Colin Buckley, Jan C Simon, Helen Stegmann, Lotte Vestergaard Tingleff
Summary : A two-compound ointment containing calcipotriol plus betamethasone dipropionate is an effective treatment for psoriasis vulgaris. The same active ingredients have now been combined in a gel formulation. Our objective was to compare the efficacy and safety of once daily treatment of the two-compound gel with the single components in the same gel vehicle and the gel vehicle alone, in patients with psoriasis vulgaris on the trunk and/or limbs. 364 patients received once daily treatment for up to 8 weeks with either the two-compound gel, the single components in the gel vehicle or the gel vehicle alone. The percentage of patients whose disease was clear or very mild and who had at least a two-step improvement in the Investigator's Global Assessment of disease severity at week 8, was significantly higher with calcipotriol plus betamethasone dipropionate (27.2%) than with betamethasone dipropionate (16.9%, p \= 0.027), calcipotriol (11.4%, p \= 0.006) or gel vehicle (0.0%, p <\; 0.001). This exploratory study showed that the two-compound gel was safe and more efficacious than its individual ingredients in the treatment of psoriasis vulgaris.
Keywords : betamethasone dipropionate, calcipotriol, combination therapy, psoriasis vulgaris

Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study